Medical/Pharmaceuticals
World's most trusted source for chemistry information, CAS, launches major biology expansion
CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...
2022-02-02 10:42
3903
yoboo rewards customers with even greater savings in the 2.2 Free Shipping Sale
MANILA, Philippines, Feb. 2, 2022 /PRNewswire/ -- The "2.2 Free Shipping Sale" has just begun. From late January toFebruary 23, babies and moms can be surprised at the yoboo store through a variety of activities such as Follow & Win, Share & Win, Cashback, discounts, and platform coupons. The eve...
2022-02-02 04:51
3106
LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 2, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized cli...
2022-02-02 01:28
2610
LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized cli...
2022-02-01 22:50
2746
Holmusk Enters into Collaboration with Metrocare Services
NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, has signed an agreement with Metrocare Services based inDallas, Texas on the use of real-world data to...
2022-02-01 22:00
3043
Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial
SYDNEY, Feb. 1, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has completed cohort 1 and advanced to cohort 2 in the64Cu...
2022-02-01 21:58
2329
New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good
TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...
2022-02-01 21:00
2941
AMR Action Fund Appoints Scientific Advisory Board
Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics BOSTON, Feb. 1, 2022 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in the development of new antibiotics, today ...
2022-02-01 19:00
3241
Cytiva fuels biotech development in Australia and New Zealand
* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...
2022-02-01 07:00
3756
DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ --
Debiopharm (www.debiopharm.com
2022-02-01 06:00
3820
Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)
SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...
2022-02-01 05:30
3050
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Feb. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vac...
2022-02-01 04:06
4938
Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement
* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...
2022-01-31 19:00
2531
Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany
STOCKHOLM, Jan. 31, 2022 /PRNewswire/ -- The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients. Together, the compa...
2022-01-31 18:00
2845
Application deadline extended for Aster Guardians Global Nursing Award worth US $250,000 to 15th Feb
* Till date more than 17300+ registrations have been received from nurses from 175 countries * The announcement comes as a response to increasing requests from nurses worldwide for more time to complete the documentation process, following the Covid-19 surge * Nurses from around the world c...
2022-01-31 15:14
4045
AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and Ivonescimab (PD-1/VEGF bi-specific antibody, research and devel...
2022-01-31 10:14
2850
AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was dosed in a Phase III registrational clinical trial of the Company's novel immuno-oncology drug, Ivonescimab (PD-1/VEGF bi-specific antibody, AK112), combined with chemotherapy versus placebo combin...
2022-01-31 09:51
2837
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital
SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...
2022-01-29 11:37
8514
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two compan...
2022-01-29 05:28
5052
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA
NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...
2022-01-28 22:00
3935
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24